The provided podcast describes the NAVULTRA Registry, an international, multicenter observational study comparing outcomes of two Transcatheter Aortic Valve Replacement (TAVR) devices: the self-expanding Navitor (NAV) and the balloon-expandable SAPIEN 3 Ultra (ULTRA). The study, involving nearly 4,000 patients, aimed to assess 1-year clinical and echocardiographic results, including all-cause death and a composite endpoint of death, disabling stroke, or heart failure rehospitalization. While primary clinical outcomes were similar between devices, the NAV group experienced higher rates of new permanent pacemaker implantation and heart failure rehospitalization. Conversely, the ULTRA device showed better performance regarding paravalvular leak, whereas NAV demonstrated superior hemodynamic performance with lower post-procedure gradients.